Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7.8% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price was down 7.8% on Tuesday . The company traded as low as $0.33 and last traded at $0.33. Approximately 39,393,920 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 30,856,506 shares. The stock had previously closed at $0.36.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $61.64 million, a PE ratio of -0.01 and a beta of 2.23. The business has a 50 day simple moving average of $0.23 and a 200 day simple moving average of $0.37.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.